Últimas noticias sobre Globus Medical (NYSE:GMED) Bolsa

Globus Medical

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.

Globus Medical, Inc. Class A Common Stock

Globus Medical Inc

Barclays analyst Dan Levy maintains American Axle &amp; Mfg Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>) with a Equal-Weight and lowers the price target from $8 to $7.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on American Axle & Mfg Hldgs, Lowers Price Target to $7

Options

Markets

Trading Ideas

RIVN

Rivian Automotive Option Alert: Feb 21 $16 Calls Sweep (16) Near The Ask: 1000 @ $0.32 vs 10551 OI; Earnings 2/20 After Close Ref=$12.9276

Barclays analyst Dan Levy maintains Adient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADNT#NYSE">ADNT</a>) with a Equal-Weight and lowers the price target from $24 to $21.

ADNT

Barclays Maintains Equal-Weight on Adient, Lowers Price Target to $21

MCTR

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Global

Abbott Exec Says Co Expects To See An Unfavorable Impact Of About 2.5% On 2025 Sales Due To A Stronger Dollar; Co May See A Change On The Regulatory Environment Which Creates Opportunity In M&A; Sees Headwinds Related To Volume-Based Procurement In China To Remain In 2025

Interactive Brokers Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) reported better-than-expected <a href="https://www.benzinga.com/25/01/43123945/customer-accounts-and-trading-volume-soar-ibkrs-q4-results-shines">fourth quarter- results</a>.
The company reported its quarterly results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
Goldman Sachs On Interactive Brokers
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6149a1cd46584a00014583f4/james-yaro">Analyst James Yaro</a> maintained a Buy rating, while raising the price target from $214 to $226.
Interactive Brokers reported its fourth-quarter adjusted earnings at $2.02 per share, beating consensus of $1.86 per share, Yaro said in a note. The results were "well-rounded," as the earnings beat was driven by 4% better net revenues and a beat of 230 basis points on margin, he added.
"Looking ahead, the company expects to conduct a number of new programming projects, and plans to increase the marketing budget, both of which should support strong account growth, around which management sounded a constructive tone," the analyst wrote. 
Given the company's guidance of lower compensation expenses as well as lower execution and clearing expenses, he raised the pre-tax margin estimate for 2025 and 2026 by 1.3 percentage points to 72.8% and by 1.2 percentage points to 72.4%.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Piper Sandler Sachs On Interactive Brokers
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/64a548c0943f950001b31bb8/patrick-moley">Analyst Patrick Moley</a> reiterated an Overweight rating, while lifting the price target from $200 to $210.
Interactive Brokers recorded an earnings beat "primarily driven by other income, Moley said. While commission and execution fees came in-line, the company's fixed expenses were around 3% "below our forecast," he added.
Annualized accounts grew by 28% in the fourth quarter and by 30% for the full year, the analyst stated. Interactive Brokers is "the best positioned U.S. brokerage platform to benefit from global growth in retail trading," he further wrote.
Keefe, Bruyette &amp; Woods On Interactive Brokers
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58f614b80bd9910001a77aea/kyle-voigt">Analyst Kyle Voigt</a> reiterated a Market Perform rating and price target of $195.
According to Voigt, Interactive Brokers reported adjusted net revenues of $1.42 billion, exceeding the consensus estimate of $1.37 billion, primarily due to higher Other Income. However, the company&#8217;s net interest income totaled $807 million, coming in slightly below the consensus estimate of $811 million.
The company's expenses totaled $347 million, coming in below the consensus estimate of $367 million, the analyst stated. "Total fixed expenses grew by +6% YoY on a reported basis in 4Q24," he further wrote.
IBKR Price Action: Shares of Interactive Brokershad were up 6.5% to $205.54 at the time of publication on Wednesday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42740273/nvidia-goldman-sachs-jefferies-financial-and-a-leading-brokerage-firm-on-cnbcs-final-trades">Nvidia, Goldman Sachs, Jefferies Financial And A Leading Brokerage Firm On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Reiteration

Movers

IBKR

Interactive Brokers Delivers 'Well-Rounded' Earnings Beat, Analysts See Global Retail Trading Growth Ahead

BNY CEO Robin Vince Says President Trump Is Clearly Trying To Attract Investment Into The Us He Wants To Drive The Us Economy Forward; On Bank Deregulation Says We Need Stability, We Need A Level Playing Field And We Need Some Predictability; Fixed Income Markets Matter; The World Needs A Lot Of Fixed Income Capital To Expect Rates To Stay High

Barclays analyst Dan Levy downgrades Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) from Overweight to Equal-Weight and lowers the price target from $13 to $11.

Downgrades

Barclays Downgrades Ford Motor to Equal-Weight, Lowers Price Target to $11

President Donald Trump's decision to revoke President Joe Biden&#8217;s executive order targeting 50% electric vehicle (EV) adoption by 2030 has <a href="https://www.benzinga.com/etfs/sector-etfs/25/01/43113169/trumps-ev-rollback-might-shake-up-etfs-winners-losers-and-teslas-unique-role-in-shifting-market">shaken the EV industry</a>, sending shares of ChargePoint Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) lower by around 3% to $1.06 since Tuesday&#8217;s session open.
What To Know: The rollback <a href="https://www.benzinga.com/etfs/sector-etfs/25/01/43113169/trumps-ev-rollback-might-shake-up-etfs-winners-losers-and-teslas-unique-role-in-shifting-market">signals</a> potential reductions in federal EV subsidies, relaxed emissions standards and limitations on state-level emissions waivers, all of which could dampen EV adoption in the United States.
Read Also: <a href="https://www.benzinga.com/trading-ideas/25/01/43116755/trumps-plan-to-end-7500-ev-tax-credits-could-be-devastating-for-telsa-rivals-poll-says-could-be-bullish-for-elon-musks-company">Trump&#8217;s Plan To End $7,500 EV Tax Credits Could Be &#8216;Devastating&#8217; For Telsa Rivals, Poll Says Could Be Bullish For Elon Musk&#8217;s Company</a>
ChargePoint, a leading EV charging network, faces direct exposure to reduced EV adoption. Fewer EV purchases could translate into slower charging infrastructure expansion, impacting the company's growth trajectory. 
Furthermore, the potential rollback of federal tax credits for EV buyers may discourage consumer adoption, leading to lower utilization rates for charging networks.
ChargePoint's near-term prospects could now clouded by policy uncertainty. Investors are closely watching state-level responses to federal policy shifts for signs of resilience in the EV ecosystem.
Read Also: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/01/42985694/chargepoint-outpaces-tesla-in-ev-network-market-share-but-jpmorgan-stays-cautious">ChargePoint Outpaces Tesla In EV Network Market Share, But JPMorgan Stays Cautious</a>
<h2 class="wp-block-heading">How To Buy CHPT Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in ChargePoint Holdings case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CHPT has a 52-week high of $2.44 and a 52-week low of $1.02.
Image courtesy of ChargePoint

CHPT

What's Going On With ChargePoint (CHPT) Stock?

Financial giants have made a conspicuous bullish move on Western Digital. Our analysis of options history for Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) revealed 12 unusual trades.
Delving into the details, we found 58% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $198,252, and 7 were calls, valued at $501,737.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $63.0 and $80.0 for Western Digital, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Western Digital's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Western Digital's significant trades, within a strike price range of $63.0 to $80.0, over the past month.
<h3>Western Digital Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737559844_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WDC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$6.15</td>
<td>$5.9</td>
<td>$6.1</td>
<td>$80.00</td>
<td>$183.0K</td>
<td>68</td>
<td>302</td>
</tr>
<tr>
<td>WDC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.05</td>
<td>$2.78</td>
<td>$2.87</td>
<td>$72.50</td>
<td>$83.5K</td>
<td>10.8K</td>
<td>304</td>
</tr>
<tr>
<td>WDC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.66</td>
<td>$1.61</td>
<td>$1.66</td>
<td>$65.00</td>
<td>$83.0K</td>
<td>4.2K</td>
<td>2.5K</td>
</tr>
<tr>
<td>WDC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$2.5</td>
<td>$2.5</td>
<td>$2.5</td>
<td>$68.00</td>
<td>$75.0K</td>
<td>3.7K</td>
<td>1.1K</td>
</tr>
<tr>
<td>WDC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$2.0</td>
<td>$1.75</td>
<td>$2.0</td>
<td>$68.00</td>
<td>$64.6K</td>
<td>3.7K</td>
<td>388</td>
</tr>
</tbody>
</table>

<h3>About Western Digital</h3>
Western Digital is a leading vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
<h3>Present Market Standing of Western Digital</h3>
<ul>
<li>With a volume of 1,783,289, the price of WDC is up 3.81% at $70.0. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 7 days.</li>
</ul>
<h3>What Analysts Are Saying About Western Digital</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $82.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $95. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Neutral rating on Western Digital, which currently sits at a price target of $70. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Western Digital, maintaining a target price of $85. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Western Digital, targeting a price of $80. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Western Digital, targeting a price of $80. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Western Digital options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Western Digital Unusual Options Activity

Deep-pocketed investors have adopted a bearish approach towards Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in OKLO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 24 extraordinary options activities for Oklo. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 50% bearish. Among these notable options, 3 are puts, totaling $141,700, and 21 are calls, amounting to $1,137,031.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $17.5 to $47.0 for Oklo over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Oklo's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Oklo's substantial trades, within a strike price spectrum from $17.5 to $47.0 over the preceding 30 days.
<h3>Oklo 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737559838_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$5.15</td>
<td>$5.0</td>
<td>$5.05</td>
<td>$35.00</td>
<td>$352.9K</td>
<td>2.3K</td>
<td align="right">772</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$3.85</td>
<td>$3.65</td>
<td>$3.85</td>
<td>$30.00</td>
<td>$76.6K</td>
<td>3.6K</td>
<td align="right">329</td>
</tr>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.85</td>
<td>$3.6</td>
<td>$3.65</td>
<td>$30.00</td>
<td>$74.3K</td>
<td>136</td>
<td align="right">206</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/28/25</td>
<td>$6.25</td>
<td>$5.8</td>
<td>$5.8</td>
<td>$30.00</td>
<td>$58.0K</td>
<td>74</td>
<td align="right">104</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$3.1</td>
<td>$2.72</td>
<td>$3.1</td>
<td>$30.00</td>
<td>$53.9K</td>
<td>3.6K</td>
<td align="right">7</td>
</tr>
</tbody>
</table>

<h3>About Oklo</h3>
Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.
Having examined the options trading patterns of Oklo, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Oklo's Current Market Status</h3>
<ul>
<li>With a trading volume of 7,825,192, the price of OKLO is up by 6.51%, reaching $33.28.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 22 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Oklo</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $31.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on Oklo, maintaining a target price of $31. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Oklo options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

OKLO

Behind the Scenes of Oklo's Latest Options Trends

Investors with a lot of money to spend have taken a bullish stance on Cameco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CCJ, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 15 options trades for Cameco.
This isn't normal.
The overall sentiment of these big-money traders is split between 66% bullish and 20%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $40,000, and 14, calls, for a total amount of $811,190.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $55.0 for Cameco over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Cameco's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cameco's whale trades within a strike price range from $20.0 to $55.0 in the last 30 days. 
<h3>Cameco Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737559833_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.99</td>
<td>$2.93</td>
<td>$2.99</td>
<td>$55.00</td>
<td>$133.6K</td>
<td>7.4K</td>
<td align="right">846</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.1</td>
<td>$55.00</td>
<td>$129.9K</td>
<td>7.4K</td>
<td align="right">761</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$38.55</td>
<td>$36.1</td>
<td>$36.3</td>
<td>$20.00</td>
<td>$108.9K</td>
<td>99</td>
<td align="right">23</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.15</td>
<td>$3.1</td>
<td>$3.15</td>
<td>$55.00</td>
<td>$60.4K</td>
<td>7.4K</td>
<td align="right">342</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.3</td>
<td>$55.00</td>
<td>$51.1K</td>
<td>5.9K</td>
<td align="right">578</td>
</tr>
</tbody>
</table>

<h3>About Cameco</h3>
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. Cameco has three reportable segments, uranium, fuel services and Westinghouse. It derives maximum revenue from Uranium Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia and United States.
Following our analysis of the options activities associated with Cameco, we pivot to a closer look at the company's own performance.
<h3>Where Is Cameco Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 1,841,642, the CCJ's price is up by 2.2%, now at $54.74. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 29 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cameco with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Behind the Scenes of Cameco's Latest Options Trends

OSI Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSIS#NASDAQ">OSIS</a>) has outperformed the market over the past 20 years by 3.99% on an annualized basis producing an average annual return of 12.51%. Currently, OSI Systems has a market capitalization of $2.88 billion. 
Buying $100 In OSIS: If an investor had bought $100 of OSIS stock 20 years ago, it would be worth $1,024.33 today based on a price of $172.60 for OSIS at the time of writing.
<h3>OSI Systems's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737559819_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OSIS

$100 Invested In OSI Systems 20 Years Ago Would Be Worth This Much Today

CL King analyst Thomas Hayes initiates coverage on JBT Marel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBTM#NYSE">JBTM</a>) with a Buy rating and announces Price Target of $143.

Initiation

JBTM

CL King Initiates Coverage On JBT Marel with Buy Rating, Announces Price Target of $143

Mobix Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares are trading higher after the company disclosed the acquisition of SCP Manufacturing <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43123261/mobix-labs-powers-into-aerospace-and-defense-with-acquisition-of-scp-manufacturing" rel="noreferrer noopener">for an undisclosed amount</a>.
SCP Manufacturing is a Nevada-based producer of mission-critical electrical components for aerospace, defense, and commercial applications.
SCP is a key supplier of mission-critical products to Spacecraft Components, which Mobix Labs agreed to <a target="_blank" href="https://www.benzinga.com//node/42160046" rel="noreferrer noopener">acquire in November 2024.</a>
SCP&#8217;s products enable Spacecraft Components to provide vital components for the U.S. Army&#8217;s Patriot Missile defense system, submarines, naval ships, oil rigs, railcars, and major metropolitan transit systems.
The buyout is expected to enhance Mobix Labs&#8217; operational efficiency, gross margins, and market position in high-growth industries.
Fabian Battaglia, CEO of Mobix Labs, said, &#8220;Our agreement to acquire SCP Manufacturing underscores Mobix Labs&#8217; determination to redefine the aerospace and defense landscape. With SCP&#8217;s engineering and manufacturing capabilities, and a track record of excellence, Mobix Labs gains access to technologies essential for advanced military and commercial systems.&#8221;
The company plans to fund the acquisition through a mix of cash and equity with earnout provisions, subject to final due diligence and board approvals. The deal is expected to close in the second quarter of 2025.
This is the company&#8217;s second acquisition in 60 days. As of September 30, 2024, the company&#8217;s cash balance<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42603691/mobix-labs-inc-announces-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener"> stood at $0.266 million</a>.
Price Action: MOBX shares are up 19.4% at $1.409 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43127009" target="_blank" rel="noreferrer noopener">Textron Reports Mixed Q4, Faces Challenges In Aviation And Industrial Segments</a></li>
</ul>
Photo via Shutterstock.

Equities

Small Cap

MOBX

Mobix Labs Secures SCP Manufacturing: Second Acquisition In 60 Days Strengthens Defense And Aerospace Supply Chain

Macro Economic Events

WIIM

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher amid strength in tech and AI stocks following the 'Stargate' $500 billion AI investment.

PLTR

Palantir Technologies Option Alert: Jan 31 $79 Calls Sweep (45) Near The Ask: 1330 @ $1.419 vs 2286 OI; Earnings 2/3 After Close Ref=$75.385

Jefferies analyst Trevor Williams maintains WEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEX#NYSE">WEX</a>) with a Hold and raises the price target from $180 to $190.

Jefferies Maintains Hold on WEX, Raises Price Target to $190

On Wednesday,&nbsp;Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $11.01 billion</a>.
Organic sales growth for the underlying base business was 8.8%. Organic growth, excluding COVID-19 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43123290/abbott-reports-fourth-quarter-and-full-year-2024-results-issues-2025-financial-outlook" rel="noreferrer noopener">testing-related sales</a> was 10.1%.
Adjusted diluted earnings per share were $1.34, in line with the analyst estimates and <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41389304/abbott-labs-path-to-double-digit-earnings-growth-in-2025-this-analyst-is-optimistic" rel="noreferrer noopener">management consensus of $1.31-$1.37</a>, up from $1.19 a year ago.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/43011207/fda-bans-red-dye-no-3-effective-january-2027-cites-cancer-risks-food-stocks-to-watch" rel="noreferrer noopener">FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch</a>
&#8220;We finished the year with very strong momentum. Sales growth and earnings per share growth in the fourth quarter were the highest of the year,&#8221; said&nbsp;Robert Ford, chairman and chief executive officer.
&#8220;We continued our track record for delivering on our commitments by achieving the upper end of our initial guidance ranges for 2024 and are well-positioned to deliver another year of strong growth in 2025.&#8221;
Medical Device sales increased 13.7% to $5.05 billion and 14% organically, including double-digit growth in the U.S. and internationally.
Several products contributed, including FreeStyle Libre, Navitor, TriClip, Amplatzer&nbsp;Amulet, and AVEIR.
In Diabetes Care, sales of continuous glucose monitors were&nbsp;$1.8 billion&nbsp;and grew 22.7% on a reported basis and 22.8% organically.
Nutrition sales increased by 4.5% to $2.07 billion (+7.1% organically). In Pediatric Nutrition, global sales increased by 1.5% (+2.5%), reflecting continued market share gains in the infant formula business. Adult nutrition sales increased 7.4% (+11.4%), led by the Ensur and Glucerna brands.
Worldwide COVID-19 testing sales were&nbsp;$176 million&nbsp;in the fourth quarter of 2024 compared to&nbsp;$288 million&nbsp;a year ago. Excluding COVID-19 testing-related sales, global Diagnostics sales increased 4.3% (+6.1%). Excluding COVID-19 testing-related sales, growth in Rapid Diagnostics was driven by strong demand for Abbott&#8217;s portfolio of respiratory disease tests.
Guidance: Abbott projects full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.16, with organic sales growth of 7.5%- 8.5% and an adjusted operating margin of 23.5%- 24.0%.
Abbott Laboratories expects first quarter 2025 adjusted EPS of $1.05-$1.09 versus consensus of $1.11.
Price Action: ABT stock is up 0.72% at $117.64 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43125966/johnson-johnson-reports-q4-earnings-above-wall-street-estimates-driven-by-strong-cancer-drugs-revenue" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook</a></li>
</ul>
Photo by Sundry Photography via Shutterstock

Biotech

Earnings

Large Cap

Guidance

Health Care

General

Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall

Tempus AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) shares are trading higher Wednesday. The stock appears to be moving on continued momentum from Tuesday&#8217;s session. Here&#8217;s a look at what <a href="https://www.benzinga.com/pressreleases/25/01/b43095975/tempus-announces-national-launch-of-olivia-its-ai-enabled-personal-health-concierge-app-for-patien">you need to know</a>. 
What To Know: Tempus AI shares surged more than 35% on Tuesday after former House Speaker&nbsp;Nancy Pelosi disclosed in a new filing that she purchased 50 call options in Tempus AI on Jan. 14. The calls have a strike price of $20 and don&#8217;t expire until Jan. 16, 2026.
Tempus AI also announced the launch of its AI-enabled personal health concierge app Olivia on Tuesday. The app allows patients to track their health-related data in one central location and leverages advanced AI to provide actionable insights.
"At Tempus, our goal has always been to improve patient outcomes by harnessing the power of data and AI. Now, as AI becomes increasingly integrated into healthcare, tools like Olivia will be essential in helping patients understand and navigate their care," said&nbsp;Eric Lefkofsky, founder and CEO of Tempus.
"This app goes beyond organizing information; it's a proactive partner empowering patients to steer their health with confidence and clarity."
Tempus AI is a technology company that aims to advance precision medicine by applying AI to healthcare.&nbsp;It&#8217;s possible that the stock is getting an additional boost Wednesday from AI optimism after U.S. President Donald Trump announced a $500 billion AI infrastructure investment <a href="https://www.benzinga.com/markets/equities/25/01/43121798/elon-musk-says-project-stargate-doesnt-actually-have-the-money-after-trump-announces-500-billion-ai-investment-led-by-softbank-oracle-and-openai">called Project Stargate</a>.
Trump on Tuesday said OpenAI, SoftBank and Oracle are planning a joint venture to build out data centers. Project Stargate and its backers have committed $100 billion for immediate investment, with up to $400 billion in additional investments expected to take place over the next four years.
TEM Price Action: <a href="http://benzinga.com/quote/tem" target="_blank" rel="noreferrer noopener">Tempus AI shares</a> closed Tuesday up approximately 35%. The stock was up another 4.1% Wednesday morning, trading at $49.68 at the time of publication, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43127554/seagate-ramps-up-technology-for-ai-delivers-profitable-growth-in-q2">Seagate Ramps Up Technology For AI, Delivers Profitable Growth In Q2</a></li>
</ul>
Photo: courtesy of Tempus AI.

What's Going On With Tempus AI Shares Wednesday?

In a report released today, David Saxon from Needham maintained a Hold rating on Globus Medical (GMED – Research Report). The company's shares clos...

Needham Keeps Their Hold Rating on Globus Medical (GMED)

BofA analyst Craig Bijou upgraded Globus Medical (GMED) to Neutral from Underperform with a price target of $97, up from $80, after the company pre...

Globus Medical upgraded to Neutral from Underperform at BofA

Globus Medical upgraded to neutral by BoA on Q4 performance

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Globus Medical (GMED – Research Report) and Reviva P...

Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and Reviva Pharmaceuticals Holdings (RVPH)

Morgan Stanley analyst Kallum Titchmarsh maintained a Buy rating on Globus Medical (GMED – Research Report) on January 8 and set a price target of ...

Positive Outlook for Globus Medical: Buy Rating Affirmed Amid Strong Q4 Results and 2025 Guidance

Globus Medical (GMED) Gets a Buy from Piper Sandler

Canaccord raised the firm's price target on Globus Medical (GMED) to $101 from $92 and keeps a Buy rating on the shares. The firm updated its model...

Globus Medical price target raised to $101 from $92 at Canaccord

Jefferies analyst Matthew Taylor maintained a Buy rating on Globus Medical (GMED – Research Report) yesterday and set a price target of $105.00. Ma...

Globus Medical's Promising Growth and Market Positioning Justify Buy Rating and Increased Price Target

BTIG analyst Ryan Zimmerman reiterated a Buy rating on Globus Medical (GMED – Research Report) today and set a price target of $91.00. The company'...

BTIG Sticks to Their Buy Rating for Globus Medical (GMED)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Globus Medical (GMED – Research Report) and QuidelOr...

Comments

Globus Medical

Noticias

Últimas noticias sobre Globus Medical (NYSE:GMED) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL